

ELISA FOR THE MEASUREMENT OF URINARY VANIN-1 AS POTENTIAL NEW BIOMARKER FOR KIDNEY INJURY

Jacqueline Wallwitz¹, Martin Alberer², Annegret Bitzer², Brigitte Eichinger¹, Elisabeth Gadermaier¹, Anna-Maria Laber¹, Gabriela Berg², Gottfried Himmler¹

¹The Antibody Lab GmbH, Vienna, Austria ²Biomedica Mediziniprodukte GmbH, Vienna, Austria

SUMMARY AND CONCLUSION

Features of the Vanin-1 (urine) sandwich ELISA:

- One-step ELISA
- Characterized antibodies
- Validated according to
- Good sample stability

The Antibody Lab

BIOMEDICA

• Optimized for urine samples

Assay range: 0 – 1200 pmol/l

FDA/ICH/EMEA guidelines

• Sample values provided



acute kidney injury, as well as for the detection of nephrotoxicant-induced renal injury, than established markers like NGAL and KIM-1.

To further study to potential of urinary Vanin-1 as biomarker for kidney injury, there is a need for a highly specific and sensitive assay that is optimized for the detection of Vanin-1 in human urine. GSGSGSGMTTQLPAY PAYVAILLFYVSRAS PAYVAILLFYVSRAS PAYVAILLFYVSRAS RASCODTFTAAVYEH TPVSREEALALMNRN NRNLDILEGAITSAA SAADQGAHIVTPED PEDAIYGWNFNRDSL DSLYPYLEDIPDFV PEVILFHDPAVTLV TLVKDFHVDTIVFPT FTAWMNVLPHLSAV SASSIEALSSGNK DSKKMTGSSIYAPNS PSKKMTGSSIYAPNS PSKKMTGSSI PSKKMTGSSIYAPNS PSKKMTGSSIYAPNS PSKKMTGSSI PSKKMTGSSI PSKKMTS PSKKMTGSSIYAPNS PSKKMTGSSI PSKKMTS PS

Epitope mapping of peptide purified capture antibody (upper panel) reveals the linear epitope at position 96-104 with the sequence LEDIPDPEV.

The detection antibody (lower panel) has 12 main linear epitopes throughout the whole sequence. **3D** structure of human Vanin-1 with designated binding sites of both antibodies. The epitope of capture antibody (pink) is located in the nitrilase domain, whereas the detection antibody can bind throughout the whole molecule. Displayed are 4 different orientations of the molecule.

domain

Active

Validation according to FDA/ICH/EMEA guidelines

Sensitivity	9.6 pmol/l (= 500 pg/ml)
Precision	Within-run (n=3): ≤ 5 % CV
Accuracy	+ 120 pmol/l: 81 % + 600 pmol/l: 93%
Parallelism	1+1: 94% 1+3: 92% 1+7: 86%
Dilution linearity	1+1: 94% 1+3: 91% 1+7: 80%

METHODS

We developed a sandwich ELISA for the quantification of human urinary Vanin-1 based on a peptide-specific capture antibody and a polyclonal detection antibody. Both antibodies were characterized regarding their

SAMPLE STABILITY

Freeze-thaw stability



SAMPLE VALUES

Nitrilase

domain

Vanin-1 urine values in apparently healthy and diseased individuals



purity and specificity.

The ELISA was validated according to ICH/FDA/EMEA guidelines, which includes the assessment of assay parameters like precision, specificity, parallelism, accuracy, and sample stability.

Vanin-1 concentrations were measured in urine samples from apparently healthy controls and subjects with impaired kidney function. **Freeze-thaw stability** of endogenous Vanin-1 was tested by comparing Vanin-1 measurements in urine samples that had undergone four freeze-thaw (F/T) cycles. Samples can undergo at least four freeze-thaw cycles. The mean recovery of sample concentrations stressed by four freeze-thaw cycles is 96%.

Benchtop stability (data not shown) of endogenous Vanin-1 was tested in a panel of urine samples. Samples can be stored for at least three hours at room temperature as well as overnight at 4° C. . **Vanin-1 values** (left panel) in urine samples from apparently healthy individuals (n=27; median = 116 pmol/l) and individuals with kidney disease (CKD) (n=24; median = 360 pmol/l).

In addition, these values were converted from pmol/l into pg/ml (conversion factor: 1 pg/ml= 0.0192 pmol/l) and **normalized to Creatinine** values (right panel). Apparently healthy individuals: median = 1131 pg Vanin-1/mg Creatinine; CKD cohort median = 3289 pg Vanin-1/mg Creatinine.

LITERATURE

- 1) Hosohata K., Washino S., Kubo T., Natsui S., Fujisaki A., Kurokawa S., Ando H., Fujimura A., Morita T. (2016): Urinary vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury. Toxicology 359–360, 71–75.
- 2) Hosohata K., Ando H., Fujimura A. (2012): Urinary vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury. J Pharmacol Exp Ther 341(3):665-62

CONTACT

Gabriela Berg: Martin Alberer:

gabriela.berg@bmgrp.com martin.alberer@bmgrp.com